CD8A and fibrosarcoma: Studies have demonstrated the superior antitumor effects of combining copper-based cuproptosis induction and cuproptosis-stimulated immunotherapy, with intravenous injection of the ES-Cu-MOF nanoparticles enriching the tumor site and inhibiting the growth of fibrosarcoma, leading to enhanced cytotoxic CD8+ T infiltration and improved antitumor immune responses.